Solidoro A, Otero J, Vallejos C, Casanova L, Salas F, Pasco T, Quiroz L, Orlandini O, Marcial J
Cancer Treat Rep. 1981 Mar-Apr;65(3-4):213-8.
Cyclophosphamide was administered to 42 patients with acute lymphocytic leukemia (ALL) as a daily continuous iv infusion at a dose of 400 mg/m2/day x 5 days; the courses of treatment were repeated every 3 weeks. Of the 42 patients entered, 21 achieved a complete response, two achieved a partial response, 12 failed to respond, and seven were considered to have early deaths. The response rate was 69.5% if only patients who received adequate trials are considered; mean duration of response was 18.5 weeks and mean survival time was 24.2 weeks. Twenty-three patients had relapsed after previous chemotherapy, and 19 patients were untreated for advanced high-risk cases of ALL; no difference was found in the response rates, durations of response, and survival times between these groups. No significant genitourinary toxicity occurred. Myelosuppression became the dose-limiting toxic effect. Continuous infusion of cyclophosphamide is a clinically effective method of ALL treatment and may have a role in the initial combination regimens for this hematologic malignancy.
对42例急性淋巴细胞白血病（ALL）患者给予环磷酰胺，以400mg/m²/天的剂量进行每日持续静脉输注，共5天；治疗疗程每3周重复一次。在纳入的42例患者中，21例达到完全缓解，2例达到部分缓解，12例无反应，7例被视为早期死亡。如果仅考虑接受充分试验的患者，缓解率为69.5%；平均缓解持续时间为18.5周，平均生存时间为24.2周。23例患者先前化疗后复发，19例患者为晚期高危ALL未接受治疗；这些组之间在缓解率、缓解持续时间和生存时间方面未发现差异。未发生明显的泌尿生殖系统毒性。骨髓抑制成为剂量限制性毒性作用。环磷酰胺持续输注是ALL治疗的一种临床有效方法，可能在这种血液系统恶性肿瘤的初始联合方案中发挥作用。
